Sarepta Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Sarepta Therapeutics has a total shareholder equity of $1.1B and total debt of $1.2B, which brings its debt-to-equity ratio to 113.9%. Its total assets and total liabilities are $3.4B and $2.3B respectively. Sarepta Therapeutics's EBIT is $38.0M making its interest coverage ratio -2.7. It has cash and short-term investments of $1.5B.
Key information
113.9%
Debt to equity ratio
US$1.23b
Debt
| Interest coverage ratio | -2.7x |
| Cash | US$1.46b |
| Equity | US$1.08b |
| Total liabilities | US$2.35b |
| Total assets | US$3.42b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AB3A's short term assets ($2.7B) exceed its short term liabilities ($688.5M).
Long Term Liabilities: AB3A's short term assets ($2.7B) exceed its long term liabilities ($1.7B).
Debt to Equity History and Analysis
Debt Level: AB3A has more cash than its total debt.
Reducing Debt: AB3A's debt to equity ratio has increased from 39.2% to 113.9% over the past 5 years.
Debt Coverage: AB3A's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: AB3A earns more interest than it pays, so coverage of interest payments is not a concern.